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Duri ng the past several years, quality-of-life has become a serious concern in the treatment of patients with cancer. Cancer screening for early detection greatly increased the chance for successful treatment, and the choice of treatment options available to cancer patients has expanded. Multimodal treatments combining surgery with chemotherapy, such as molecular-targeted drugs and radiotherapy, have improved both overall and disease-free survival. However, these treatments occasionally involve acute, chronic, and delayed treatment toxicities. A regimen that considers treatment benefits, complications, and side effects needs to be developed. Moreover, qualityof-life and activities of daily living are key aspects that also need to be considered in decisions about cancer care and treatment. Because most cancer patients have impairment and disability during various stages of their illness, the demand for cancer rehabilitation, from the early period of diagnosis to the terminal stage, is increasing. Previous investigations have indicated that rehabilitation significantly improves the motor functions and cognitive functions of cancer patients. Induced by both exacerbation of the disease and side effects of treatment, various changes occur in physical functions and abilities. Rehabilitation specialists must evaluate the neuromuscular, musculoskeletal, and functional status of the patients properly to devise more effective training programs for improving their status. Such a measurement must be a single task assessment that is both usable in daily clinical practice and suitable for various stages of cancer. Furthermore, the measurement must be able to detect changes in a timely fashion after they occur.
To date, the Eastern Cooperative Oncology GroupYPerformance Status (ECOG-PS), 1 the Karnofsky Performance Scale (KPS), 2 the Palliative Performance Scale (PPS), 3 and the Edmonton Functional Assessment ToolY2 (EFAT-2) 4 have been developed as physical function scales of cancer patients. Using these scales, the general condition and performance status of cancer patients can be understood. These are also used to determine whether patients can receive chemotherapy and as a prognostic tool for survival in palliative care. However, when used in cancer rehabilitation, these have the following limitations: (1) discrimination between impairment and disability of the patients is not clear, (2) some evaluation standards lack objectivity, (3) the evaluation standard may not be able to assess the small changes of physical function, and (4) these cannot adapt to the recent changes in cancer treatment strategies such as the need for hospitalization. Therefore, it is necessary to develop a new tool to measure physical functions that is easy to administer, short, reliable, valid, and responsive to clinical changes during rehabilitation interventions. The purpose of this study was to develop and confirm the psychometric properties of the Cancer Functional Assessment Set (cFAS), a new tool for evaluating physical functions in cancer patients.
METHODS

Participants
The participants were 119 cancer inpatients at varying stages of illness. Sixty-nine inpatients were recruited from June 2009 to February 2010 at Shizuoka Cancer Center (SCC), and 50 inpatients (20 for interrater reliability testing and 30 for cross-validation study) were recruited from August 2010 to August 2011 at Keio University Hospital (KUH). The inclusion criteria were (1) patients who received cancer treatment and (2) patients who underwent physiotherapy and/or occupational therapy. The exclusion criteria were (1) patients who had difficulty in communicating and various other conditions judged unsuitable for entry by the attending physician and (2) patients who underwent rehabilitation for functional deficits not related to cancer and its treatment.
Study Design
Development and validation of the cFAS took place in three phases: phase 1, item generation; phase 2, item reduction; and phase 3, evaluation of psychometric properties. The study was approved by the Ethical Committee of SCC and KUH according to the guidelines of the Helsinki declaration, and informed consent was obtained from the patient.
Phase 1: Item Generation
Systematic reviews related to cancer rehabilitation were retrieved from MEDLINE and EMBASE from December 2003 to December 2008. Guyatt et al. 5 have highlighted the importance of consensus expert opinion as it relates to evidence-based medicine. A round-table discussion was undertaken, and 32 board-certified physiatrists with a minimum of 10 yrs' experience in rehabilitation medicine were asked to list factors relevant to impairments and disabilities of cancer patients. When developing the cFAS, a minimum number of items required for the evaluation of impairments in daily clinical practice, a single task assessment, and suitability for various stages of cancer were the basic principles considered.
Phase 2: Item Reduction
The strategy for item reduction was guided by a desire to ensure item relevance and fit with patient values. Reactivity to functional changes and evaluation practicality in cancer patients were particularly important. The data of 45 inpatients at SCC in whom repeated evaluation was possible were used. Items that showed good response to changes or were clinically important were retained. The standardized response mean (SRM), 6 the ratio between the mean change score and the standard deviation of that change score within the same group, was calculated to assess the responsiveness of each item. An SRM of approximately 0.20 is considered small, whereas 0.50 indicates moderate responsiveness, and greater than 0.80 is considered highly sensitive. 6 Items with low responsiveness and those that most patients could not perform were excluded.
Phase 3: Psychometric Properties of the cFAS
The data of 69 inpatients at SCC were used to assess concurrent validity and internal reliability of the cFAS. Concurrent validity of the cFAS was assessed by correlating the total cFAS score with the other performance tools (ECOG-PS, KPS, and Functional Independence Measure [FIM] instrument 7 ), measured at the same time, using Spearman correlation coefficients. Cronbach alpha was calculated to determine the degree of internal reliability of the 24 items of the cFAS. This coefficient is considered acceptable when it is greater than 0.7, according to Nunnally 8 criterion.
Interrater reliability testing was conducted in 20 inpatients at KUH. Two raters evaluated each patient with the cFAS independently within a 24-hr period. To estimate interrater reliability, weighted kappa statistics were used for the 24 items, and the intraclass correlation coefficient (ICC; 2,1) was used for the total cFAS score. Weighted kappa statistics are frequently used for scale items that contain more than two possible responses to more accurately reflect the amount of disagreement among observers. According to conventional cutoffs for interpreting kappa statistics, reliability was interpreted as almost perfect (0.81Y1.00), substantial (0.61Y0.80), or moderate (0.41Y0.60). 9 An ICC of 0.7 is commonly used as a threshold of acceptable reliability. 10 Another 30 inpatients at KUH were recruited for the cross-validation study. The same rater assessed the cFAS at two different hospitals, SCC and KUH, to examine concurrent validity and internal consistency.
As additional evaluation, the responsiveness of the total cFAS score was assessed. The SRM was used to evaluate the responsiveness of the total cFAS score, the ECOG-PS, the KPS, and the FIM instrument. Physical function was measured either before rehabilitation intervention or once weekly after the initiation of rehabilitation. A data set of 75 inpatients in whom repeated evaluation was possible at both hospitals was used.
The Statistical Package for the Social Sciences for Macintosh, version 18.0 (Statistical Package for the Social Sciences Inc, Chicago, IL), was used for all statistical analyses, setting the significance level at less than 5%. Gastrointestinal  33  21  5  7  Lung  20  13  3  4  Hematologic  15  8  1  6  Brain  15  13  0  2  Genitourinary  10  1  3  6  Head and neck  9  5  3  1  Other  17  8  5  4 RESULTS Table 1 shows the characteristics of the 119 patients (37.8% women, 62.2% men; mean age, 64.1 yrs).
Phase 1: Item Generation
Eight instruments 1Y4,7,11Y13 were identified in the systematic review. Those instruments served as a framework from which to guide an expert consensus on cancer rehabilitation. The initial item pool contained 41 items that were commonly affected in cancer patients and considered fundamental to functional performance. These included shoulder abduction passive range of motion (ROM), knee extension passive ROM, ankle dorsiflexion passive ROM, grip strength, iliopsoas manual muscle testing (MMT), 14 
Phase 2: Item Reduction
At first, each item chosen in phase 1 was graded from 0 to 3 or 0 to 5. A rating of 0 represents a total loss of function, whereas a rating of 3 or 5 represents optimal function. The following items whose SRM level was less than 0.50 were excluded: knee extension passive ROM, sitting balance, kneemouth test of the Stroke Impairment Assessment Set, finger function test of the Stroke Impairment Assessment Set, rolling over, locomotion, communication, motivation for rehabilitation, and consciousness state. Although the responsiveness of the lower and upper extremity sensory function items was small (0.26 and 0.43), these were not excluded. This is because these are valuable items for cancer patients who have neural deficits as a result of treatment complications and direct invasion of the tumor. Items that were judged to be inappropriate for cancer patients were the finger floor distance, the Timed Up & Go test, the number of times the patient stood up in 30 secs, and intellectual function.
Their achievement quotients were less than 0.90. The remaining 24 items constituted the cFAS ( Table 2) .
Sit up/stand up/transfer/walk/stairs ascending and descending are basic activities of daily living. For the sit up, stand up, transfer, 50 m-walk, and stairs ascending and descending items, the amount of assistance scored is purely regarding the physical assistance given to the patient and does not take into account other factors such as number of steps climbed or distance walked. Grip strength is also a marker of physical fitness and muscle strength. The MMT of the iliopsoas and the abdomen can screen for steroid myopathy. The quadri ceps muscle strength is important for basic activities. Sensory function and the MMT of the tibialis anterior are useful for peroneal neuropathy. Body sway with feet together, eyes closed for 1 min, is an indicator of position sense. The one foot standing with eyes open task is a test of static balance. Ankle dorsiflexion passive ROM with knee flexed can assess the tightness of the triceps surae and the heel cord. Shoulder abduction passive ROM is able to pick up the functional disorder such as adhesive capsulitis of the shoulder.
Phase 3: Evaluating Psychometric Properties
The Spearman correlation coefficients between the total cFAS score and the ECOG-PS, the KPS, and the FIM instrument were j0.79 (P G 0.0001), 0.75 (P G 0.0001), and 0.73 (P G 0.0001), respectively. Cronbach alpha was 0.92 for the total score, indicating sufficient reliability according to Nunnally criterion. Using weighted kappa for scale items, agreement among investigators ranged from substantial (0.74) to almost perfect (1.00) ( Table 3 ). The ICC (2,1) for the total cFAS score was 0.97 and had acceptable reliability.
There were no significant differences in the mean age, sex, and primary tumor type between samples of the two hospitals (Table 1 ). There were also no significant between-sample differences in the mean total cFAS score (SCC, 66.83 [17.39] ; KUH, 67.27 [19.72] ). Cronbach > was 0.91 for the total scale, indicating sufficient reliability for research purposes. The Spearman correlation coefficients between the total cFAS score and the ECOG-PS, the KPS, and the FIM instrument were j0.82 (P G 0.0001), r = 0.85 (P G 0.0001), and 0.86 (P G 0.0001), respectively. Table 4 shows the SRM for the total cFAS score, the ECOG-PS, the KPS, and the FIM instrument.
www.ajpmr.com The patient rests in the 45-degree semireclining position in a wheelchair or high-back chair and is asked to raise the shoulders off the back of the chair and assume a sitting position. L/E, lower extremity; Lt, left; Rt, right; U/E, upper extremity.
The SRM was higher for the cFAS than for the other rating scales, regardless of the treatment regimen.
DISCUSSION
Need for an Instrument to Assess Physical Functions of Cancer Patients
One of the goals of this study was to develop the cFAS (Table 2) , a new tool for measurement of physical functions in phase 1 and 2 cancer patients. Cancer rehabilitation involves helping cancer patients obtain optimal physical, social, psychologic, and vocational functioning within the limits imposed by the disease and its treatment. 19 Physical functions must be evaluated in detail to offer appropriate rehabilitation, and rehabilitation goals need to be modified in consideration of physical functioning and patients' prognosis. Objective data also play a pivotal role as a common language for healthcare professionals, and these must be useful in multidisciplinary care. Furthermore, cancer rehabilitation can be better demonstrated to medical professionals of other specialized fields if the effects of rehabilitation can be shown by an objective physical function scale.
As physical function scales of cancer patients, the ECOG-PS, the KPS, the PPS, and the EFAT-2 have been developed to date. The ECOG-PS and the 13, 22 Even though the ECOG-PS, the KPS, and the PPS are simple and help one to easily grasp the patient's general condition, these cannot describe why the patient's activities are limited. It has also been suggested that the scores on the ECOG-PS and the KPS for patients with terminal cancer had a Bfloor effect.[ 4 Although the PPS and the EFAT-2 are scales that are specialized for end-of-life care, their evaluation criteria are vague.
Because cancer rehabilitation involves adaptation in various stages of the illness, a measure for patients with cancer must be usable in various stages of the illness. To get more insight into the physical status and to plan more effective treatment programs for patients with cancer in accordance to their physical conditions, impairments and disabilities must be assessed.
The newly developed cFAS assesses impairments in daily clinical practice without the need for a special tool. In the present study, the SRMs of the ECOG-PS, the KPS, and the FIM instrument were uneven, depending on the treatment regimens, but the SRM of the cFAS maintained the same responsiveness across the regimens at a higher level than the other scales. The cFAS can be considered a highly detailed scale that can evaluate the physical function changes of patients with cancer, regardless of treatment regimen, during various stages.
Psychometric Properties of the cFAS
The second goal of this study was to evaluate the psychometric properties in phase 3. The measurement tool had to possess the following characteristics: reliability, validity, internal consistency, responsiveness, and practicality. 23 Reliability refers to the reproducibility of a measurement. Validity is an index as to how well any evaluation tool actually measures what it intends to measure. Internal consistency is the extent to which a test assesses the same characteristics. Responsiveness refers to the ability of an evaluation tool to detect clinically relevant changes.
The strong correlations of the cFAS with the ECOG-PS, the KPS, and the FIM instrument demonstrate its concurrent validity with the existing scales that have been used to measure the effects of cancer rehabilitation. The Cronbach alpha coefficient for the cFAS exceeded Nunnally criterion of 0.7, which demonstrates acceptable internal consistency of the cFAS. Concerning the interrater reliability, weighted kappa statistics for the 24 items of the cFAS and ICC for the total cFAS score demonstrated sufficient reliability (Table 3) . These results indicate that the estimates of the interrater reliability of the cFAS are acceptable.
Furthermore, cross-validation was performed. In an independent sample, it was confirmed that Cronbach alpha coefficients for the total cFAS were acceptable and that the cFAS had strong correlations with the existing scales. The newly developed cFAS can be performed in daily clinical practice; it is based on single-task assessment, and it can be completed in 5Y10 mins. Furthermore, it does not require special training to perform the assessment because the evaluation standard is clear.
These results indicate that the cFAS is a reliable, valid, responsive, and practical instrument. Furthermore, the cross-validity of the cFAS was confirmed in another sample.
Advantages of the cFAS
The psychometric properties discussed above indicate that the cFAS can be very useful in daily clinical practice, as well as in clinical research.
Its advantages over other existing instruments are the following: (1) It is developed on the basis of the World Health Organization model of International Classification of Impairments, Disabilities, and Handicaps and therefore shows physical function definitely. It is useful to plan more effective rehabilitation programs and change the goal of rehabilitation intervention in accordance with a patient's condition. (2) It is usable to evaluate any cancer patient.
(3) It is based on single-task assessment and can be performed in daily clinical practice. (4) It does not require special training to perform the assessment because the evaluation standard is clear. (5) It is sufficiently responsive to changes. (6) It is responsive regardless of the treatment regimen and appropriate for clinical application to various cancer patients.
This study, however, suggested room for further improvement of the cFAS. The cFAS cannot evaluate physical fitness because it was developed as a scale evaluable in daily clinical practice. It also does not describe the symptoms (physical and psychologic complaints) of the patients. The authors will try to evaluate these symptoms using an additional scale. The cFAS with the symptom scale might be more useful for outcome studies in cancer rehabilitation. It also needs to be validated in not only the inpatient but also the outpatient population. Lastly, the limited sample size makes it difficult to draw broader conclusions on the basis of tumor types and resulting impairments.
CONCLUSIONS
The cFAS meets most of the requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to important clinical changes. Furthermore, it is superior to existing scales as a tool for, and a potential contributor to the development of, cancer rehabilitation.
